![Melanoma - ASCO 2021 Skin Cancer Highlights - Skin Cancer - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options Melanoma - ASCO 2021 Skin Cancer Highlights - Skin Cancer - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/conferences/2021/clinical-oncology-2021/skin/melanoma_slide_thumb/melanoma_slide_thumb-2.png?rev=9a4124158ba64e8ab42f202682b054e6)
Melanoma - ASCO 2021 Skin Cancer Highlights - Skin Cancer - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options
![Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a51eabe5-5fcc-41e9-a8d2-131e135f4d7a/gr3.jpg)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology
![Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e3947409-2537-4e51-bb60-7d3f7818fc2d/gr4.jpg)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology
![Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/52c41546-392d-4834-a98c-2fe8fac43e2c/gr2_lrg.jpg)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology
![Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma | SCF - Skin Cancer Foundation Provider Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma | SCF - Skin Cancer Foundation Provider](https://provider.skincancer.org/wp-content/uploads/Figure-1-chart.jpg)
Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma | SCF - Skin Cancer Foundation Provider
![References in Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology References in Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/ca77e65d-a8f4-4d37-84f3-7bb5f4b335a3/gr3_lrg.jpg)
References in Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology
![Figure 5 | Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma Figure 5 | Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma](https://media.springernature.com/full/springer-static/image/art%3A10.1007%2Fs41669-018-0080-5/MediaObjects/41669_2018_80_Fig5_HTML.gif)
Figure 5 | Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
![Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial - Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b316d514-43f8-43ee-b998-0cbc54128a98/gr1_lrg.jpg)
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -
![Supplemental Materials for Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019 - European Journal of Cancer Supplemental Materials for Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019 - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/cf2ca322-bf68-4aee-9e50-42f54cf7cb4c/fx1_lrg.jpg)
Supplemental Materials for Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019 - European Journal of Cancer
![Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma - AIM at Melanoma Foundation Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma - AIM at Melanoma Foundation](https://www.aimatmelanoma.org/wp-content/uploads/Blogging-Tips-LinkedIn-Post-Header-25.png)
Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma - AIM at Melanoma Foundation
![Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial - Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1c1d46c3-5cce-4707-a74a-3c3b160780ac/gr2_lrg.jpg)
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -
![Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs41669-018-0112-1/MediaObjects/41669_2018_112_Fig2_HTML.png)
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink
![PDF] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | Semantic Scholar PDF] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/05d8ec52e94baed4fc4663945cff5b66471673c8/4-Figure3-1.png)
PDF] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | Semantic Scholar
![NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter](https://pbs.twimg.com/media/DJbom06UEAAQejo.jpg)
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
![SciELO - Brasil - Treatment of advanced melanoma - A changing landscape Treatment of advanced melanoma - A changing landscape SciELO - Brasil - Treatment of advanced melanoma - A changing landscape Treatment of advanced melanoma - A changing landscape](https://minio.scielo.br/documentstore/1806-9282/4LH988cHYNSgxBPmP7znMwG/5120c2a43d233dc44210c5d2af68f7afd8880a38.jpg)
SciELO - Brasil - Treatment of advanced melanoma - A changing landscape Treatment of advanced melanoma - A changing landscape
![a) Progression-free survival (PFS) and (b) overall survival (OS). CI,... | Download Scientific Diagram a) Progression-free survival (PFS) and (b) overall survival (OS). CI,... | Download Scientific Diagram](https://www.researchgate.net/publication/343940004/figure/fig1/AS:983955708854272@1611604730580/a-Progression-free-survival-PFS-and-b-overall-survival-OS-CI-confidence.png)